COMMUNIQUÉS West-GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2018 Preliminary Selected Financial Results; Provides 2019 Revenue Guidance

31/01/2019 - 22:05

2018 revenue of $251.2 million, an increase of 58 percent from 2017 Fourth quarter revenue of $66.8 million, an increase of 25 percent from fourth quarter 2017 Repurchase in the fourth quarter of 1.1 million shares of [...]

Integra LifeSciences to Host Fourth Quarter and Full-Year 2018 Earnings Results Conference Call on February 21, 2019

31/01/2019 - 22:01

PLAINSBORO, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full-year 2018 financial results [...]

Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock

31/01/2019 - 22:01

RUTHERFORD, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today [...]

The NFL Alumni Leads the Way in Brain Health Awareness Through Participation in The Living Brain Project

31/01/2019 - 20:16

Brookfield, WI, Jan. 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Trident Brands Inc. (OTCQB: TDNT), a biotech and nutraceutical company, through their Brain Armor® subsidiary, is pleased to announce that the NFL [...]

ICC Partnership Brings Innovative Solutions to EU Medical Market -- CFN Media

31/01/2019 - 19:22

SEATTLE, Jan. 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]

Neovacs announces its clinical advisory board meeting to design the Phase III Study for IFNalpha Kinoide in lupus - Paris February 11th

31/01/2019 - 17:45

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES ITS CLINICAL ADVISORY BOARD MEETING TO DESIGN THE PHASE III STUDY FOR IFN-K IN LUPUS MEETING TO BE HELD IN PARIS, FEBRUARY 11 TH Paris and Boston, January [...]

Néovacs annonce la constitution de son comité clinique en vue de la préparation de la Phase III avec l'IFNalpha Kinoide en Lupus - 11 février à Paris

31/01/2019 - 17:45

COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS ANNONCE LA CONSTITUTION DE SON COMITÉ CLINIQUE EN VUE DE LA PREPARATION DE LA PHASE III AVEC L’IFNα KINOÏDE EN LUPUS LA RÉUNION SE TIENDRA LE 11 [...]

Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over

31/01/2019 - 17:36

Company Announcement Genmab, Janssen and MorphoSys have agreed to end the patent infringement lawsuit launched by MorphoSys AG relating to DARZALEX On January 25, 2019, a summary judgement decision ruled that the three [...]

Invitation to Idorsia's full year financial results 2018 webcast and conference call

31/01/2019 - 17:36

Idorsia will publish its full year financial results 2018 on Thursday February 7, 2019, at 07:00 CET. An investor conference call and webcast will be held to discuss the results on the same day: Date: Thursday, February [...]

Invitation to Novozymes' annual shareholders' meeting 2019

31/01/2019 - 16:34

Read the full announcement in PDF. Attachment E-mail notice EN

Nancy J. Sandy Appointed Chief Executive Officer of Taconic Biosciences

31/01/2019 - 16:01

RENSSELAER, N.Y., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences’ Board of Directors has selected Nancy J. Sandy to succeed Dr. Robert J. Rosenthal as Chief Executive Officer (CEO). Effective January 14, Ms. [...]

Innovation Pharmaceuticals Establishing European Subsidiary; CEO Increases Equity Stake in IPIX

31/01/2019 - 15:30

BEVERLY, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, today announces that the Company is establishing a wholly-owned [...]

UTMD Reports Audited Year 2018 and Fourth Quarter Financial Performance

31/01/2019 - 15:00

SALT LAKE CITY, Jan. 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Excluding a large favorable adjustment correcting the U.S. repatriation tax (REPAT) on foreign subsidiary cash and cumulative earnings (E&P), [...]

Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe

31/01/2019 - 15:00

CRESTWOOD, Ky., WALTHAM, Mass. and ZUG, Switzerland, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel [...]

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

31/01/2019 - 14:57

HAMILTON, Bermuda, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”, “we”, and “our”) announced today the pricing of its public offering of 2,654,984 Class A common shares at a [...]

Sandoz Canada demeure parmi les meilleurs employeurs à Montréal et obtient la certification Meilleur employeur au Canada pour l’année 2019

31/01/2019 - 14:30

Sandoz Canada se classe pour une deuxième année consécutive comme l’un des meilleurs employeurs à Montréal. L’entreprise figurait également parmi les 100 meilleurs employeurs au Canada en 2017. Sandoz a été certifiée [...]

Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines

31/01/2019 - 14:30

FREMONT, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a post [...]

Sapience Therapeutics to Present at 2019 BIO CEO & Investor Conference

31/01/2019 - 14:30

HARRISON, N.Y., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications [...]

AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies

31/01/2019 - 14:30

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) [...]